|IAS 2016 St. Petersburg, Russia|
last updated: February 20, 2017
To access some of the content on athero.org
you must be a registered user and you must log on.
You can use the interface on the right side of this page to either log on or to register.
| From the IAS President's Desk |
IAS SEVERE FH PANEL
IAS Consensus Statement “Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel”
The International Atherosclerosis Society (IAS) is proud to announce the publication on the definition of severe FH and the implications for clinical management in The Lancet Diabetes and Endocrinology. The IAS Severe FH Panel, made of 25 internationally renowned experts and chaired by Dr. Raul Santos, worked with the objective of characterizing the severe FH phenotype and made recommendations on how to stratify CVD risk and to whom to prescribe the novel lipid lowering treatments. These recommendations will contribute to improved daily clinical practice and better management of FH patients.
To download the full text, which is open access, please link to and register at http://www.thelancet.com/journals/landia/article/PIIS2213-8587(16)30041-9/fulltext (Published online May 27, 2016). For more information about The Lancet, please visit The Lancet Homepage at www.thelancet.com.
Other FH activities
Improving management through genetic testing for Familial Hypercholesterolaemia (FH)
This e-learning has been developed for healthcare professionals with an interest in FH and genetic testing by a panel of world renowned experts in this area, Pr. Carrie and Pr. Bruckert from France, and Dr. Ballantyne and Dr. Eng in the USA and is approved by the International Atherosclerosis Society (IAS).
On completion of this e-learning you will have a better understanding of:
You can view the e-learning at http://www.cor2ed.com
- Key aspects of genetic testing in Familial Hypercholesterolaemia (FH)
- How and why to use genetic testing
- How to interpret results
- How to use cascade screening to identify related individuals at risk
FIRST DYSLIPIDEMIA and FH CLINIC in IRAQ
The establishment of the first dyslipidemia and FH clinic in Iraq by Dr. Mutaz Al-Sabah – a research, diagnostic and therapeutic center at the Al-Diwaniyah teaching hospital which will ultimately separate the FH clinic in the future as an independent center dealing with familial lipid disorders. Dr. Al-Sabah has also attended the first IAS-OSLA course on Lipid Metabolism and Cardiovascular Risk held in Muscat-Oman in February 2015 and has been a very active member of the IAS-OSLA Community since then.
Link to event photos
The International Atherosclerosis Society (IAS) and Oman Society of Lipid & Atherosclerosis (OSLA) are organizing the Third IAS-OSLA Course “Lipid Metabolism and Cardiovascular Risk”
to be held in Muscat, Oman, on February 24-27, 2017.
| IAS - OSLA Collaboration in the MENA Region |
As in 2015 and 2016, the aim of this Course is to increase the knowledge and experience of early- to mid-career, English-speaking practicing clinicians interested in the management of lipid disorders
and will be restricted to 30 clinicians from the Middle East and North Africa (MENA) region who manage patients with lipid disorders.
For more information please link to the program agenda.
To view all highlights, please click here
| Meeting and Educational Activity Highlights |
The IAS wishes to thank all the supporters which have generously offered grants to the IAS for the development of its many activities and in support of its mission:|
Aegerion Pharmaceuticals, Amgen, Inc., Amgen (Europe) GmbH, Daiichi Sankyo Co., Ltd., Fondazione Giovanni Lorenzini, OSLA - Oman Society of Lipids and Atherosclerosis, Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd.,Pfizer, Sanofi and Regeneron, and Weill Cornell Medical College
This site is optimised for a min. 1024 x 768 pixels resolution
The International Atherosclerosis Society (IAS), incorporated in 1979, promotes, at an international level, the advancement of science, research and teaching in the field of atherosclerosis and related diseases.
|IAS Newsletter Editors & Website Editorial Board|
Scott M. Grundy, MD, PhD
Dallas, TX, USA
Houston, TX, USA
Commentary & Newsletter Editor
(Dallas, TX, USA)